Amino-aza-adamantane derivatives and methods of use
View Patent ↗The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to α7 nicotinic acetylcholine receptors also are described.
1. A compound of formula (I)
or a pharmaceutically acceptable salt or prodrug thereof, wherein
X 1 is a bond or is selected from the group consisting of —O—, —O-alkylene, —NR 2 — and —NR 2 -alkylene, wherein the oxygen atom of —O-alkylene and the nitrogen atom of —NR 2 -alkylene is attached to the parent molecular moiety;
A is —Ar 2 —Y—Ar 3 ;
Ar 2 is selected from the group consisting of aryl and heteroaryl, wherein Ar 2 is unsubstituted or substituted with a substituent selected from alkyl, haloalkyl and nitro;
Ar 3 is selected from the group consisting of aryl and heteroaryl, wherein Ar 3 is unsubstituted or substituted with a substituent selected from alkyl, haloalkyl and nitro;
Y is a bond or —O—; and
R 1 , R 2 and R 3 are individually selected from the group consisting of hydrogen and C 1 -C 6 alkyl.
2. The compound according to claim 1 , wherein
X 1 is a bond;
Ar 2 is selected from the group consisting of phenyl, a 5 or 6 membered monocyclic heteroaryl ring and a bicyclic heteroaryl ring, wherein Ar 2 is substituted or unsubstituted wherein each substituent is independently selected from the group consisting of alkyl, haloalkyl, and nitro; and
Ar 3 is selected from the group consisting of phenyl, a 5 or 6 membered monocyclic heteroaryl ring and a bicyclic heteroaryl ring, wherein Ar 3 is substituted or unsubstituted wherein each substituent is independently selected from the group consisting of alkyl, haloalkyl and nitro.
3. The compound according to claim 1 , wherein
X 1 is a bond;
Ar 2 is selected from the group consisting of phenyl and a 5 or 6 membered monocyclic heteroaryl ring, wherein Ar 2 is substituted or unsubstituted wherein each substituent is independently selected from the group consisting of alkyl, haloalkyl and nitro; and
Ar 3 is selected from the group consisting of phenyl, a 5 or 6 membered monocyclic heteroaryl ring and a bicyclic heteroaryl ring, wherein Ar 3 is substituted or unsubstituted wherein each substituent is independently selected from the group consisting of alkyl, haloalkyl and nitro.
4. The compound according to claim 1 , wherein
X 1 is a bond;
Ar 2 is phenyl which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alk alkyl, haloalkyl and nitro; and
Ar 3 is selected from the group consisting of phenyl, a 5 or 6 membered monocyclic heteroaryl ring and a bicyclic heteroaryl ring, wherein Ar 3 is substituted or unsubstituted wherein each substituent is independently selected from the group consisting of alkyl, haloalkyl and nitro.
5. The compound according to claim 1 , wherein
X 1 is a bond;
Ar 2 is a 5 or 6 membered monocyclic heteroaryl ring which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl, haloalkyl and nitro; and
Ar 3 is selected from the group consisting of phenyl, a 5 or 6 membered monocyclic heteroaryl ring and a bicyclic heteroaryl ring, wherein Ar 3 is substituted or unsubstituted wherein each substituent is independently selected from the group consisting of alkyl, haloalkyl and nitro.
6. The compound according to claim 1 , wherein
X 1 is a bond;
Ar 2 is a bicyclic heteroaryl ring which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkyl, haloalkyl and nitro; and
Ar 3 is selected from the group consisting of phenyl, a 5 or 6 membered monocyclic heteroaryl ring and a bicyclic heteroaryl ring, wherein Ar 3 is substituted or unsubstituted wherein each substituent is independently selected from the group consisting of alkyl, haloalkyl and nitro.
7. The compound selected from the group consisting of
4-phenylthiophene-2-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
4-phenylthiophene-2-carboxylic acid (4s)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-phenylthiophene-2-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-phenylthiophene-2-carboxylic acid (4s)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-(pyridin-2-yl)-thiophene-2-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-(pyridin-2-yl)-thiophene-2-carboxylic acid (4s)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
2,2′-bithiophene-5-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
2,2′-bithiophene-5-carboxylic acid (4s)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-(3-trifluoromethylphenyl)-furan-2-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-(3-trifluoromethylphenyl)-furan-2-carboxylic acid (4s)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-(2-nitrophenyl)-furan-2-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-(2-nitrophenyl)-furan-2-carboxylic acid (4s)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
2-(pyridin-4-yl)-thiazole-2-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
2-(pyridin-4-yl)-thiazole-2-carboxylic acid (4s)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
2-(thiophen-2-yl)-thiazole-4-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
5-(thiophen-2-yl)-1H-pyrazole-3-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
N-[(4r)-1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl]-4-(thiophen-2-yl)-benzamide;
N-[(4s)-1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl]-4-(thiophen-2-yl)-benzamide;
5-(2-methylthiazol-4-yl)thiophene-2-carboxylic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide; and
3-(thiophen-2-yl)benzoic acid (4r)-(1-azatricyclo[3.3.1.1 3,7 ]dec-4-yl)-amide;
or a pharmaceutically acceptable salt thereof.